
AbstractWe retrospectively analyzed high-risk ALL patients in CR1 receiving total body irradiation based conditioning regimen with ATLG (n = 74) or PTCy (n = 73) for GVHD prophylaxis. The 3-year OS and LFS were similar in both groups: 65 and 60% in the ATLG group and 64 and 67% in the PTCy group (p = 0.9 and 0.5, respectively). CIR and NRM rate at three years was 12 and 21% after PTCy and 19 and 20% after ATLG (p = 0.4 and p = 0.9, respectively). Acute GvHD grades II-IV and grades III/IV at 100 days was 46 and 19% after PTCy and 33 and 10% after ATLG (p = 0.08 and p = 0.9, respectively). Chronic GvHD of all grade at two years was higher after PTCy: 55% versus 26% (p < 0.001). Based on the propensity score matching (PSM) analysis, aGvHD grades II-IV was trending higher in the PTCy group compared to the ATLG group (p = 0.07). In contrast to the PSM analysis, on multivariate analysis the receipt of PTCy compared with ATLG was associated with a reduced CIR (p = 0.026). Our retrospective single-center analysis shows a lower incidence of acute and chronic GvHD while displaying similar LFS and OS after ATLG compared to PTCy in TBI based allogeneic stem cell transplantation for high-risk ALL.
Male, Adult, Transplantation Conditioning, Adolescent, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Transplantation Conditioning/methods [MeSH] ; Allografts [MeSH] ; Cyclophosphamide/therapeutic use [MeSH] ; /692/699/1541/1990/283 ; Cyclophosphamide/administration ; Male [MeSH] ; Child [MeSH] ; Graft vs Host Disease/prevention ; Adolescent [MeSH] ; Female [MeSH] ; Transplantation, Homologous/methods [MeSH] ; Antilymphocyte Serum/therapeutic use [MeSH] ; Adult [MeSH] ; Humans [MeSH] ; Retrospective Studies [MeSH] ; Middle Aged [MeSH] ; Hematopoietic Stem Cell Transplantation/adverse effects [MeSH] ; Article ; Antilymphocyte Serum/administration ; Transplantation Conditioning/adverse effects [MeSH] ; Young Adult [MeSH] ; Hematopoietic Stem Cell Transplantation/methods [MeSH] ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy [MeSH] ; /692/308/2171 ; article, Allografts, Article, Young Adult, Humans, Transplantation, Homologous, Female, Child, Cyclophosphamide, Retrospective Studies, Antilymphocyte Serum
Male, Adult, Transplantation Conditioning, Adolescent, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Transplantation Conditioning/methods [MeSH] ; Allografts [MeSH] ; Cyclophosphamide/therapeutic use [MeSH] ; /692/699/1541/1990/283 ; Cyclophosphamide/administration ; Male [MeSH] ; Child [MeSH] ; Graft vs Host Disease/prevention ; Adolescent [MeSH] ; Female [MeSH] ; Transplantation, Homologous/methods [MeSH] ; Antilymphocyte Serum/therapeutic use [MeSH] ; Adult [MeSH] ; Humans [MeSH] ; Retrospective Studies [MeSH] ; Middle Aged [MeSH] ; Hematopoietic Stem Cell Transplantation/adverse effects [MeSH] ; Article ; Antilymphocyte Serum/administration ; Transplantation Conditioning/adverse effects [MeSH] ; Young Adult [MeSH] ; Hematopoietic Stem Cell Transplantation/methods [MeSH] ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy [MeSH] ; /692/308/2171 ; article, Allografts, Article, Young Adult, Humans, Transplantation, Homologous, Female, Child, Cyclophosphamide, Retrospective Studies, Antilymphocyte Serum
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 1 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
